Stock Analyst Note
Merck KGaA Earnings: Raises 2024 Outlook Slightly, but No Fair Value Estimate Change
Narrow-moat Merck KGaA's second-quarter results looked strong, and management slightly raised its 2024 outlook on momentum in its healthcare and electronics segments. At first glance, mild changes to our assumptions do not materially affect our fair value estimate, though. Shares remain fairly valued.